In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.
A novel tool for rapidly identifying the genetic “fingerprints” of cancer cells may enable future surgeons to more accurately ...
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Con ...
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.
A novel tool for rapidly identifying the genetic "fingerprints" of cancer cells may enable future surgeons to more accurately remove brain tumors while a patient is in the operating room, new research ...
A new research paper was published in , Volume 16, on February 18, 2025, titled "Leukopenia, weight loss and oral mucositis induced by 5-Fluorouracil in hamsters' model: A regenerative approach using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback